Naptumomab estafenatox
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Mouse |
Target | 5T4 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C3255H5025N855O1050S18 |
Molar mass | 73.5 kg/mol g·mol−1 |
|
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
- Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S; Lassen, U (2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of Clinical Oncology. 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC 2734423. PMID 19636016.
- ClinicalTrials.gov
- WHO Drug Information
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.